HK Stock Market Move | GENFLEET-B(02595) rose by over 3%, with two items GFH375/VS-7375 preclinical studies being selected for groundbreaking research abstracts.

GENFLEET-B (02595) rose more than 3%, reaching a 3.4% increase as of the time of writing, at 46.8 Hong Kong dollars, with a turnover of 15.9244 million Hong Kong dollars. On the news front, on April 23, according to an official announcement from GENFLEET-B on their official Weibo account, the company announced that the results of multiple preclinical studies of GFH375/VS-7375 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in 2026, with two of the research data being selected as Late-breaking research abstracts. The studies presented explore the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating the anti-resistance potential of GFH375 surpassing KRAS G12D (ON) inhibitors, and providing solid scientific evidence for various combination therapies. The experiments presented at this meeting were led by Vertex Pharmaceuticals' partner, Verastem Oncology. In 2025, GFH375 entered the world's first Phase III registered clinical trial for an oral KRAS G12D inhibitor in China. In 2026, GFH375 was the first to receive breakthrough therapy designation for two domestic KRAS G12D inhibitor monotherapies, used to treat G12D mutant pancreatic cancer and non-small cell lung cancer (NSCLC) respectively. Additionally, the product has been granted Fast Track qualification by the US FDA for various-line treatments for G12D mutant metastatic pancreatic adenocarcinoma (PDAC). Currently, multiple monotherapy and combination therapy trials of GFH375/VS-7375 are ongoing both domestically and internationally.